Pitcairn Co. Sells 7,675 Shares of Edwards Lifesciences Co. (NYSE:EW)

Pitcairn Co. trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 33.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,025 shares of the medical research company's stock after selling 7,675 shares during the quarter. Pitcairn Co.'s holdings in Edwards Lifesciences were worth $1,112,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at about $26,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $30,000. Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $54,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 2.6 %

EW traded down $1.81 during trading on Thursday, reaching $68.10. The company had a trading volume of 1,763,519 shares, compared to its average volume of 4,875,339. The business's fifty day moving average price is $71.43 and its 200 day moving average price is $70.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a market cap of $40.03 billion, a P/E ratio of 9.82, a PEG ratio of 4.82 and a beta of 1.15.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,853 shares of company stock valued at $4,534,247. Corporate insiders own 1.29% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on EW. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research report on Thursday, February 13th. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Finally, Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.